<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858713</url>
  </required_header>
  <id_info>
    <org_study_id>2016-002143-42</org_study_id>
    <nct_id>NCT02858713</nct_id>
  </id_info>
  <brief_title>Adherence in Topical Treatment of Psoriasis</brief_title>
  <official_title>Can an App Supporting Psoriasis Patients Improve Adherence to Topical Treatment? A Single-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medical adherence to topical corticosteroid products in psoriasis patients is a main
      determinant for poor treatment effect.

      The investigators aim to test if a multifaceted intervention delivered in an app (MyPso
      QualityCareTM owned by Leo Pharma) for smartphones combined with an Electronic Monitor (EM)
      (Teslo) can improve medical adherence among psoriasis patients treated with a topical
      calcipotriol/betamethasone dipropionate foam combination (Cal/BD) (Enstilar©).

      The study is classified as a phase 4 study, since it is studied if improved use of Enstilar©
      results in improved treatment outcomes.

      Link to published study protocol:

      https://bmcdermatol.biomedcentral.com/articles/10.1186/s12895-018-0071-3

      Link to published results from the study:

      https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16667
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and methods Intervention: Participants in the intervention group download a patient
      supporting app (MyPso SmarTop™ Version 1.0, owned by Leo Pharma) which combined with an EM
      (SmarTop™ number 053776, owned by Leo Pharma) has three functions: 1) Measures use of
      medication through EM, 2) measures degree of psoriasis by patients tracking symptoms, and 3)
      supports the patient with treatment and refill reminders.

      Study type: Single-blind block randomized controlled trial. Sampling: Patients are sampled
      from the dermatology out-patient clinic at Odense University Hospital.

      Eligibility criteria: Psoriasis patients aged 18-75 years with mild-moderate psoriasis. It is
      mandatory that patients have a smartphone and basic skills for use of the smartphone.

      Estimated sample size: To be able to improve medical adherence, the investigators wish to
      detect an 8 % difference between number of applications between intervention and control arm
      in use of Enstilar© over a 4 week treatment period. Confidence Interval (two-sided) using 95
      % C.I., power 80, ratio of sample size 1, mean number of application in intervention Group 90
      % of recommended daily application / 4 weeks, S.D. 15 %, drop-outs maximum 10 %:

      Total sample size: 134 participants All participants will be seen by trial principal
      investigator at all of the study visits.

      Disclosure and informed signed consent will be obtained before inclusion: The patients are
      aware they test new equipments, but not informed that they are being monitored or the purpose
      of the study.

      Randomization: Single-blind block randomized controlled trial. Procedure: At the first study
      visit the trial investigator obtains information regarding gender, age and estimates use of
      Enstilar© for 4 weeks based on involved Body Surface Area (BSA).

      For randomization the investigators use blocks based on 1) age and 2) gender.

      Procedures at baseline study visit: While the patient fills the Dermatology Life Quality
      Index (DLQI) questionnaire, the trial investigator inserts baseline data into the programme
      REsearch Data Capture (REDCap©) randomize, which randomizes into an intervention- and control
      arm. Both intervention- and control group receive Enstilar© in the consultation.

      To avoid attrition bias from the prescribing doctor, knowledge regarding which patients that
      are randomized for the intervention is restricted to one nurse until last study visit. After
      the consultation the patient is referred to a nearby room, where the nurse has access to see
      into which group the participant has been randomized. If the participant is randomized to the
      app group, the nurse will instruct the patient in how to download the app on their smartphone
      and give standard of care instructions regarding how to adhere to the treatment plan. The
      participants in the control group will reveive standard of care instructions from the nurse
      regarding how to adhere to the treatment plan. The nurse will not disclose that the patient
      is being monitored. At the baseline visit the nurse delivers free study medication
      (Enstilar©) to all participants.

      Baseline: Medical history, socio-economic data, DLQI (Dermatology Life Quality Index) and
      LS-PGA (Lattice System Physician's Global Assessment).

      Primary outcome measure week 4: Rate of secondary nonadherence to Enstilar© is obtained using
      three different Measurements:

      Estimated use 0.5 g Enstilar© / % Body Surface Area (BSA) involved / use of Enstilar© in a
      4-week treatment period (measured by weight of Enstilar© cans)

      Number of estimated applications in the treatment period / Number of Applied applications in
      the treatment period (measured by EM)

      Reported by the patient on an interval scale

      Secondary outcome measures week 4, 8, and 26: DLQI and LS-PGA. At study visit week 4 the
      patients return the EM to the investigator.

      Conclusion: If the app for smartphones with the EM can improve adherence and significantly
      improve secondary outcome measures long-term (week 26), there are promising potentials for
      implementing the app in the clinic. To the investigators knowledge, this is the first study
      in topically treated psoriasis, testing if an intervention delivered by in app for
      smartphones can improve medical adherence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">August 29, 2017</completion_date>
  <primary_completion_date type="Actual">April 29, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Adherent Participants</measure>
    <time_frame>Week 4</time_frame>
    <description>Rate of adherent patients, defined as dichotomized adherence rates obtained by number of days with applied medication with a selected cut-off of 80%, with adherence rates above 80% considered adherent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Baseline, week 4, 8 and 26</time_frame>
    <description>Change from baseline to week 4
Description of Dermatology Life Quality Index (DLQI): A score from 0-30 [0, patients' quality of life not affected; 30, patients' quality of life severely affected by the skin disease]. The DLQI-scale is a summary of 10 questions on subscales, where patients' report how severely their quality of life has been affected for the last week (patient reported outcome measurements (PROM), each subscale have a score from 0 (not affected by skin disease) to 3 (severely affected by skin disease).
The minimum score is 0 and the highest score is 30, a high score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lattice-System Physician's Global Assessment (LS-PGA)</measure>
    <time_frame>Week 4, 8 and 26</time_frame>
    <description>Change from baseline to week 4, 8 and 26
Lattice System Physican's Gloabal Assessment (LS-PGA) is a measure from 0-8 (0, patients skin clear; 8, patients' skin severely affected by psoriasis). The scale is a summary of three subscales: 1). thickness of psoriasis, 2). extent of scaling and 3). body surface ares (BSA) affected. The minimum score is 0 and the maximum score is 8, a high score represents a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Adherence</condition>
  <arm_group>
    <arm_group_label>App as intervention + Enstilar©</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional instructions + Enstilar©</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriene + Betamethasone Dipropionate</intervention_name>
    <description>Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.</description>
    <arm_group_label>App as intervention + Enstilar©</arm_group_label>
    <other_name>Enstilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>App</intervention_name>
    <description>App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.</description>
    <arm_group_label>App as intervention + Enstilar©</arm_group_label>
    <other_name>Mypso app</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Psoriasis patients aged 18-75 years with mild-moderate psoriasis. It is mandatory that
             patients have a smartphone and basic skills for use of the smartphone.

        Exclusion Criteria:

          -  aged under 18 and above 75 years, guttate psoriasis, severe degree of psoriasis, i.e.
             pustular and erythrodermic psoriasis, lack of smartphone and user skills for the
             smartphone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathias Tiedemann Svendsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Allergy Centre, Odense University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology and Allergy Centre</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16667</url>
    <description>Study results</description>
  </link>
  <reference>
    <citation>Svendsen MT, Andersen F, Andersen KH, Andersen KE. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial. BMC Dermatol. 2018 Feb 7;18(1):2. doi: 10.1186/s12895-018-0071-3.</citation>
    <PMID>29415699</PMID>
  </reference>
  <results_reference>
    <citation>Svendsen MT, Andersen F, Andersen KH, Pottegård A, Johannessen H, Möller S, August B, Feldman SR, Andersen KE. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol. 2018 Nov;179(5):1062-1071. doi: 10.1111/bjd.16667. Epub 2018 Jul 5.</citation>
    <PMID>29654699</PMID>
  </results_reference>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <results_first_submitted>December 11, 2017</results_first_submitted>
  <results_first_submitted_qc>February 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>February 17, 2019</last_update_submitted>
  <last_update_submitted_qc>February 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Mathias Tiedemann Svendsen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT02858713/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>App as Intervention + Enstilar©</title>
          <description>Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
Enstilar 0.005%-0.064% Topical Foam</description>
        </group>
        <group group_id="P2">
          <title>Conventional Instructions + Enstilar©</title>
          <description>Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
Enstilar 0.005%-0.064% Topical Foam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>App as Intervention + Enstilar©</title>
          <description>Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
Enstilar 0.005%-0.064% Topical Foam</description>
        </group>
        <group group_id="B2">
          <title>Conventional Instructions + Enstilar©</title>
          <description>Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
Enstilar 0.005%-0.064% Topical Foam</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="23" upper_limit="75"/>
                    <measurement group_id="B2" value="48" lower_limit="21" upper_limit="72"/>
                    <measurement group_id="B3" value="48" lower_limit="21" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Adherent Participants</title>
        <description>Rate of adherent patients, defined as dichotomized adherence rates obtained by number of days with applied medication with a selected cut-off of 80%, with adherence rates above 80% considered adherent</description>
        <time_frame>Week 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>App as Intervention + Enstilar©</title>
            <description>Patients prescribed Enstilar© receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
Enstilar 0.005%-0.064% Topical Foam</description>
          </group>
          <group group_id="O2">
            <title>Conventional Instructions + Enstilar©</title>
            <description>Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
Enstilar 0.005%-0.064% Topical Foam</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Adherent Participants</title>
          <description>Rate of adherent patients, defined as dichotomized adherence rates obtained by number of days with applied medication with a selected cut-off of 80%, with adherence rates above 80% considered adherent</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="53" upper_limit="77"/>
                    <measurement group_id="O2" value="38" lower_limit="26" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.004</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>6.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dermatology Life Quality Index (DLQI)</title>
        <description>Change from baseline to week 4
Description of Dermatology Life Quality Index (DLQI): A score from 0-30 [0, patients' quality of life not affected; 30, patients' quality of life severely affected by the skin disease]. The DLQI-scale is a summary of 10 questions on subscales, where patients' report how severely their quality of life has been affected for the last week (patient reported outcome measurements (PROM), each subscale have a score from 0 (not affected by skin disease) to 3 (severely affected by skin disease).
The minimum score is 0 and the highest score is 30, a high score means worse outcome.</description>
        <time_frame>Baseline, week 4, 8 and 26</time_frame>
        <population>Patients lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Instructions + Enstilar©</title>
            <description>Conventional Instructions + Enstilar© Changing from baseline to week 4</description>
          </group>
          <group group_id="O2">
            <title>App as Intervention + Enstilar©</title>
            <description>App as intervention + Enstilar© Changing from baseline to week 4</description>
          </group>
        </group_list>
        <measure>
          <title>Dermatology Life Quality Index (DLQI)</title>
          <description>Change from baseline to week 4
Description of Dermatology Life Quality Index (DLQI): A score from 0-30 [0, patients' quality of life not affected; 30, patients' quality of life severely affected by the skin disease]. The DLQI-scale is a summary of 10 questions on subscales, where patients' report how severely their quality of life has been affected for the last week (patient reported outcome measurements (PROM), each subscale have a score from 0 (not affected by skin disease) to 3 (severely affected by skin disease).
The minimum score is 0 and the highest score is 30, a high score means worse outcome.</description>
          <population>Patients lost to follow-up</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54" lower_limit="3.47" upper_limit="5.61"/>
                    <measurement group_id="O2" value="4.12" lower_limit="3.27" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" lower_limit="3.92" upper_limit="6.43"/>
                    <measurement group_id="O2" value="4.59" lower_limit="3.71" upper_limit="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="3.69" upper_limit="6.31"/>
                    <measurement group_id="O2" value="4.23" lower_limit="3.25" upper_limit="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DLQI: Change baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.545</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>-0.415</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.770</ci_lower_limit>
            <ci_upper_limit>0.939</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DLQI: Change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.545</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>-0.415</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.770</ci_lower_limit>
            <ci_upper_limit>0.939</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DLQI: Change from baseline to week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.450</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>-0.581</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.099</ci_lower_limit>
            <ci_upper_limit>0.938</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>DLQI: Change from baseline to week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>-0.770</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.389</ci_lower_limit>
            <ci_upper_limit>0.848</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lattice-System Physician's Global Assessment (LS-PGA)</title>
        <description>Change from baseline to week 4, 8 and 26
Lattice System Physican's Gloabal Assessment (LS-PGA) is a measure from 0-8 (0, patients skin clear; 8, patients' skin severely affected by psoriasis). The scale is a summary of three subscales: 1). thickness of psoriasis, 2). extent of scaling and 3). body surface ares (BSA) affected. The minimum score is 0 and the maximum score is 8, a high score represents a worse outcome.</description>
        <time_frame>Week 4, 8 and 26</time_frame>
        <population>Lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Conventional Instructions + Enstilar©</title>
            <description>Conventional Instructions + Enstilar© arm changing in LS-PGA form baseline to week 26.</description>
          </group>
          <group group_id="O2">
            <title>App + Enstilar©</title>
            <description>App + Enstilar© arm changing in LS-PGA from baseline to week 26</description>
          </group>
        </group_list>
        <measure>
          <title>Lattice-System Physician's Global Assessment (LS-PGA)</title>
          <description>Change from baseline to week 4, 8 and 26
Lattice System Physican's Gloabal Assessment (LS-PGA) is a measure from 0-8 (0, patients skin clear; 8, patients' skin severely affected by psoriasis). The scale is a summary of three subscales: 1). thickness of psoriasis, 2). extent of scaling and 3). body surface ares (BSA) affected. The minimum score is 0 and the maximum score is 8, a high score represents a worse outcome.</description>
          <population>Lost to follow-up</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from baseline to week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" lower_limit="1.17" upper_limit="1.75"/>
                    <measurement group_id="O2" value="1.86" lower_limit="1.59" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" lower_limit="1.86" upper_limit="2.46"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.96" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" lower_limit="1.49" upper_limit="2.11"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.66" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS-PGA: Change from baseline to week 4</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Regression, Linear</method>
            <param_type>coefficient</param_type>
            <param_value>0.400</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.795</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS-PGA: Change from baseline to week 8</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.662</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>0.091</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.321</ci_lower_limit>
            <ci_upper_limit>0.504</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS-PGA: Change from baseline to week 26</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.424</p_value>
            <method>Regression, Linear</method>
            <param_type>Coefficient</param_type>
            <param_value>0.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.264</ci_lower_limit>
            <ci_upper_limit>0.625</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Information on adverse events systematically reported at visits at baseline, week 4, 8 and 26 (6 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conventional Instructions + App as Intervention + Enstilar©</title>
          <description>Information obtained baseline, week 4, 8 and 26.
Participants were treated with Enstilar© once daily when needed for 6 months</description>
        </group>
        <group group_id="E2">
          <title>App as Intervention + Enstilar©</title>
          <description>Information obtained baseline, week 4, 8 and 26.
Participants were treated with Enstilar© once daily when needed for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infection in knee prosthesis</sub_title>
                <description>Infection in knee prosthesis. Not Associated with the use of Cal/BD foam.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <description>Elevated liver enzymes after treatment with methotrexate. Not related to use of Cal/BD foam</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung and skin infections</sub_title>
                <description>Not related to the use of Cal/BD foam</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>various musculoskelatal disorders</sub_title>
                <description>Not related to the use of Cal/BD foam</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>relapse of carcinoma in situ of the glottis</sub_title>
                <description>Not related to use of Cal/BD foam</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinin levels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of chronic obstructive pumonary disease (COPD)</sub_title>
                <description>Associated to accidentally inhaling gas from canister containing Cal/BD foam</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin manifestations</sub_title>
                <description>11 different skin manifestations not directly related to use of Enstilar</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Fainting</sub_title>
                <description>Fainting not related to use of Cal/BD foam</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>M.D. Mathias Tiedemann Svendsen</name_or_title>
      <organization>Department of Dermatology, Odense University Hospital</organization>
      <phone>+45 61265827</phone>
      <email>m_tiedemann@hotmail.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

